W
Waiv
AI precision tests for oncology
About Waiv
Waiv develops AI-powered precision tests for oncology and biomarker-driven care. Spun out of Owkin as Waiv (formerly Owkin Dx) and based in Paris, the company turns digital pathology and multimodal clinical data into clinically oriented diagnostics and biomarker tools for patients, clinicians, and biopharma partners.
Its product suite includes RlapsRisk BC for breast cancer risk profiling, the MSIntuit Suite, and BRCAura, alongside the Destra deployment platform. The company applies machine learning and foundation models to histopathology to support biomarker discovery, risk and outcome prediction, treatment-response assessment, and pathology workflow integration. Public materials highlight long-running medical AI research heritage from Owkin, collaborations with biopharma and clinical institutions, and clinician- as well as biopharma-facing offerings. An MSD collaboration around MSIntuit is part of the product history and should not be read as the company founding date.
Waiv sells AI diagnostics and biomarker solutions to healthcare providers, laboratories, and biopharmaceutical teams scaling precision oncology. It is headquartered in Paris, France.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2026
- Headquarters
- Paris, France
- Employees
- 52
- Open positions
- None listed
- Dealroom signal
- 82.3/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Biotechnology, Oncology, Biomarkers, Innovation Radar, AI for medical imaging, DT and LS, observatoire healthtech
- Technology
- Artificial Intelligence, Deep Tech, Machine Learning, Deep Learning
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Apr 2026 | $35M | $140M | Serena · Alpha Intelligence Capital · OTB Ventures · SISTAFUND | ↗ |
| CORPORATE SPINOUT✓Other financing | Feb 2026 | $0 | — | Owkin | — |
Growth signals
Latest recorded traffic for Waiv is 2.5K monthly website visits, up 323.7% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Alpha Intelligence Capital
OTB Ventures
Serena
SISTAFUND
Karista
CRB Health Tech
Series B and later1 investor entered at this stage
Owkin
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Waiv on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Waiv’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.